 Evogene Ltd. NASDAQ: EVGN TASE: EVGN.TA, a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its participation in the CRISPR-IL consortium. The goal is to develop Go-Genome, an artificial intelligence AI based, end-to-end system for genome-editing to be used in multi-species for pharma, agriculture, and aquaculture. Evogenes CSO, Dr. Eyal Emmanuel will serve as the Chairman of the consortium. 